SCHEMBL5881740

SCHEMBL5881740

Cc1ccc(C=CS(=O)(=O)NC(=O)c2ccc3[nH]c(C)c(Cc4ccc(Cl)cc4Cl)c3c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 2/20 0.39
MAPT P10636 2/20 0.38
MGAM O43451 2/20 0.38
GAA P10253 2/20 0.38
SI P14410 2/20 0.38
MGAM2 Q2M2H8 2/20 0.38
CNR1 P21554 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
KDM4E B2RXH2 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PTGS2 P35354 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
MCL1 Q07820 1/20 0.36
GUSB P08236 2/20 0.36
PTPN5 P54829 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5881737 1.00 SNCA (0.39) SNCAMAPTMGAMGAASI
SCHEMBL5882071 0.93 MAPT (0.42) SNCAMAPTCNR1LMNATP53
SCHEMBL5882069 0.93 MAPT (0.42) SNCAMAPTCNR1LMNATP53
SCHEMBL5881849 0.92 PTPN5 (0.48) SNCAMAPTCNR1HDAC8MAOA
SCHEMBL5881853 0.92 PTPN5 (0.48) SNCAMAPTCNR1HDAC8MAOA
SCHEMBL5882143 0.87 PPARG (0.40) SNCAMAPTCNR1LMNATP53
SCHEMBL5882138 0.87 PPARG (0.40) SNCAMAPTCNR1LMNATP53
SCHEMBL5881768 0.86 FLT1 (0.51) SNCAMAPTMGAMGAASI
SCHEMBL5881661 0.85 SNCA (0.38) SNCAMAPTMGAMGAASI
SCHEMBL6135073 0.84 MAPT (0.41) MAPTGAALMNATP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115647-B2 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. (US) 2006-10-03 US disclosed
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. 2002-10-03 US disclosed
US-6410584-B1 ANTICANCER AGENTS CELL PATHWAYS, INC. 2002-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives IDO1, IDO2, INMT SNCA 930/4885MAPT 4038/4885MGAM 3169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.